EUVIMEDEUVIMED entdecken
Crossref

The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients

Neval Ete Wareham iD, Victoria S Kjærgaard iD, Mohammed Habib iD, Joanne Reekie iD, Kasper Rossing, Henrik Sengeløv iD, Marlyse Buisson, Jean-Luc Lenormand iD, Michael Perch iD, Nicolai Schultz, Nikolai Kirkby, Søren S Sørensen iD und 4 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiaf477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Neval Ete Wareham und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Lymphoproliferative Disorders, Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Infections, Herpesvirus 4, Human. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Danish National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplant and hematopoietic stem cell transplant recipients, and is often associated with Epstein-Barr virus (EBV) reactivation. The sZEBRA protein, a soluble form of the EBV nuclear immediate-early antigen BZLF1 (also called Zta), plays a crucial role in EBV reactivation and immune evasion. This study aimed to externally validate an association between sZEBRA and the diagnosis of PTLD.

Methods

In this retrospective case-control study, the relative odds of having PTLD according to sZEBRA plasma levels at diagnosis of PTLD and comparable follow-up for controls was analyzed using logistic regression adjusting for demographics, transplant information, and sample timing. The model was further adjusted for corresponding EBV PCR plasma levels. The level of sZEBRA was fitted in the model either as present/absent or in quartiles.

Results

Thirty-three (17%) PTLD cases and 161 (83%) controls were included. The adjusted odds ratio (aOR) of a positive versus negative sZEBRA test for PTLD diagnosis was 2.82 (95% confidence interval [CI], 1.37–7.68); after additional adjustment for EBV PCR levels, the aOR was 4.15 (95% CI, 1.31–13.14). Separating sZEBRA levels into quartiles, aOR of sZEBRA in the fourth quartile was 12.43 (95% CI, 1.99–77.55) compared to a negative result in the fully adjusted model.

Conclusions

Elevated sZEBRA levels, especially those in the highest quartile and when combined with EBV PCR, were associated with PTLD and may serve as a complementary biomarker to EBV PCR to identify patients with PTLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoproliferative DisordersHematopoietic Stem Cell TransplantationEpstein-Barr Virus InfectionsHerpesvirus 4, HumanTrans-ActivatorsOrgan TransplantationHumansMaleFemaleRetrospective StudiesCase-Control StudiesMiddle AgedAdultTransplant RecipientsYoung AdultAdolescentBiomarkers

Stichwörter der Autor:innen

Epstein-Barr virusinfectionposttransplant lymphoproliferative diseasetransplantation

Substanzen

BZLF1 protein, Herpesvirus 4, HumanTrans-ActivatorsBiomarkers

Autor:innen und Institutionen

  • Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, Copenhagen, Denmark.
  • Department of Virology, University Grenoble Hospital, Grenoble, France.
  • Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
  • Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
  • Techniques de l'Ingénierie Médicale et de la Complexité (TIMC) Laboratory, UMR 5525 The French National Centre for Scientific Research (CNRS)-Université Grenoble Alpes (UGA), Grenoble, France.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Neval Ete Wareham, Victoria S Kjærgaard, Mohammed Habib, Joanne Reekie, Henrik Sengeløv, Jean-Luc Lenormand, Michael Perch, Søren S Sørensen, Julien Lupo, Daniel D Murray

Förderung

  • Danish National Research Foundation

Zitieren

APA

Wareham, N. E., Kjærgaard, V. S., Habib, M., Reekie, J., Rossing, K., Sengeløv, H., Buisson, M., Lenormand, J. L., Perch, M., Schultz, N., Kirkby, N., Sørensen, S. S., Lupo, J., Lundgren, J. D., Murray, D. D., & Drouet, E. (2026). The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf477

Vancouver

Wareham NE, Kjærgaard VS, Habib M, Reekie J, Rossing K, Sengeløv H, et al. The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf477

BibTeX
@article{Wareham2026,
  author = {Wareham, Neval Ete and Kjærgaard, Victoria S and Habib, Mohammed and Reekie, Joanne and Rossing, Kasper and Sengeløv, Henrik and Buisson, Marlyse and Lenormand, Jean-Luc and Perch, Michael and Schultz, Nicolai and Kirkby, Nikolai and Sørensen, Søren S and Lupo, Julien and Lundgren, Jens D and Murray, Daniel D and Drouet, Emmanuel},
  title = {The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiaf477}
}
Kostenlos starten →